Names
Mosunetuzumab-axgb Lunsumio™Indications and usage
Mosunetuzumab-axgb is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Side effects needing medical attention
The most common adverse reactions include cytokine release syndrome, fever, chills, low blood pressure, fast or irregular heartbeat, tiredness or weakness, difficulty breathing, headache, confusion, feeling anxious, dizziness or light-headedness, nausea, vomiting, rash.